Drug discovery startup Atomwise, which joined the NVIDIA Inception virtual accelerator program in 2018, developed AtomNet, a convolutional neural network for small molecule drug discovery. The AtomNet AI technology can screen more than 16 billion compounds in less than two days using the scalability of NVIDIA GPUs hosted in the cloud. Virtual screening can accelerate the time it takes to discover potential drug candidates that may be promising for further testing and development, especially for challenging targets that were previously considered “undruggable.”
Read the full article on NVIDIA's blog.
About Atomwise
Atomwise is revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets across 775 collaborations spanning more than 250 partners around the world. Our portfolio of joint ventures and partnerships with leading pharmaceutical, agrochemical, and emerging biotechnology companies represents a collective deal value approaching $7 billion. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.
